Recently, a CEO I know (I’ll call him Jeff) invited me to weigh in on a corporate strategy initiative that his company was undertaking. Jeff and his leadership team had been focused on day-to-day ...

Formulation can make or break a development-stage protein drug, and add years of IP protection and value for post-patent molecules. Yet significant disagreement exists on the best time to undertake ...